Betta Pharmaceuticals Co., Ltd. (SZ300558), established in 2003 in Hangzhou, China, is one of the leading Chinese pharmaceutical companies dedicated to develop and commercialize innovative oncology products to meet high unmet medical needs in China. With over 1,400 employees in Hangzhou and Beijing, Betta's development capabilities range from small molecule and biologics discovery, clinical development, registration, manufacturing, sales and marketing. Betta's first product - icotinib, the first innovative oncology product developed and commercially launched by a domestic company - is a blockbuster targeted therapy treating EGFR+ non-small cell lung cancer patients, having achieved 1.55 billion RMB annual sales in 2019. Betta currently has two products on the market, with three more being launched within the next year, and additional 13 programs under clinical development. Betta has also set up collaborations with top biopharmas and biotechs around the world such as Amgen, Merus and Agenus.
